AstraZeneca PLC has reportedly priced a €2.55 billion Eurobond offering through its subsidiary AstraZeneca Finance LLC, maturing across four tranches between 2030 and 2038.
The offering includes a €700 million tranche due March 1, 2030, carrying a 3.402% coupon, and a €600 million tranche maturing September 1, 2032, with a 3.652% coupon. A €500 million tranche due September 1, 2035, carries a 3.923% coupon, while a €750 million tranche due September 1, 2038, offers a 4.169% coupon.
Net proceeds from the issuance are reportedly to be allocated toward general corporate purposes, aligning with AstraZeneca’s long-term funding strategy. The bonds were priced on Sunday and are expected to close on September 1, 2026, subject to customary conditions.
The Euro Medium Term Note programme underpins the issuance, with the notes admitted to listing on the UK Financial Conduct Authority’s Official List and trading on the London Stock Exchange’s Main Market. The notes are unregistered under the U.S. Securities Act of 1933 and are not eligible for sale in the United States without registration or an applicable exemption.
Joint book-running managers for the transaction were reported to be Barclays Bank PLC, Goldman Sachs International, and Morgan Stanley. AstraZeneca, headquartered in Cambridge, UK, operates as a biopharmaceutical company focused on prescription medicines in oncology, rare diseases, and biopharmaceuticals.
